Piper Jaffray analyst Edward Tenthoff said he would remain a buyer of Arrowhead Pharmaceuticals shares ahead of a “busy” second half of the year. The company could have five RNAi candidates in the clinic this year, and partner Amgen (AMGN) nominated AMG-890 as a clinical candidate that could begin clinical trials this year. Tenthoff reiterated an Overweight rating and $17 price target on Arrowhead shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.